LT2004074A - Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti - Google Patents

Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti

Info

Publication number: LT2004074A
Authority: LT; Lithuania
Prior art keywords: neoplazinems; metalproteinazes; matricines; ligoms; kompozicija
Prior art date: 2002-01-08

Application number

LT2004074A

Other languages

English (en)

Other versions

LT5215B (lt

Inventor

Matthias Rath

Shrirang Netke

Vadim Ivanov

Waheed Roomi

Aleksandra Niedzwiecki

Original Assignee

Matthias Rath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-08

Filing date

2004-08-05

Publication date

2004-12-27

2004-08-05 Application filed by Matthias Rath filed Critical Matthias Rath

2004-12-27 Publication of LT2004074A publication Critical patent/LT2004074A/lt

2005-05-25 Publication of LT5215B publication Critical patent/LT5215B/lt

Links

CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
229960005070 ascorbic acid Drugs 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract 1
235000005487 catechin Nutrition 0.000 abstract 1
-1 catechin compound Chemical class 0.000 abstract 1
229950001002 cianidanol Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Inorganic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)

LT2004074A 2002-01-08 2004-08-05 Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti LT5215B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/041,427 US6939860B2 (en)	2002-01-08	2002-01-08	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds

Publications (2)

Publication Number	Publication Date
LT2004074A true LT2004074A (lt)	2004-12-27
LT5215B LT5215B (lt)	2005-05-25

Family

ID=21916454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2004074A LT5215B (lt)	2002-01-08	2004-08-05	Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti

Country Status (29)

Country	Link
US (3)	US6939860B2 (lt)
EP (1)	EP1463498B1 (lt)
JP (1)	JP4144800B2 (lt)
KR (1)	KR20050005408A (lt)
CN (1)	CN1612731A (lt)
AT (1)	ATE439833T1 (lt)
AU (2)	AU2002244690A1 (lt)
BR (1)	BR0208052A (lt)
CA (1)	CA2469162A1 (lt)
CZ (1)	CZ2004853A3 (lt)
DE (1)	DE60233433D1 (lt)
EE (1)	EE200400031A (lt)
ES (1)	ES2332126T3 (lt)
HR (1)	HRP20040705A2 (lt)
HU (1)	HUP0402421A3 (lt)
IL (1)	IL162384A0 (lt)
LT (1)	LT5215B (lt)
LV (1)	LV13249B (lt)
MX (1)	MXPA04006627A (lt)
NO (1)	NO20033949L (lt)
NZ (1)	NZ533353A (lt)
PL (1)	PL371205A1 (lt)
RU (1)	RU2284185C2 (lt)
SI (1)	SI21871A (lt)
SK (1)	SK2772004A3 (lt)
TR (1)	TR200401669T1 (lt)
UA (1)	UA78979C2 (lt)
WO (1)	WO2003057211A1 (lt)
ZA (1)	ZA200404915B (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8669282B2 (en) *	2000-10-31	2014-03-11	Hill's Pet Nutrition, Inc.	Companion animal compositions including lipoic acid and methods of use thereof
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
US20050079234A1 (en) *	2003-08-27	2005-04-14	Chiang Yang Chi	Compositions comprising herbs and method for immunomodulation
KR20050070385A (ko) *	2003-12-30	2005-07-07	(주)현덕비엔티	폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물
US20080160099A1 (en) *	2004-11-10	2008-07-03	The Trustees Of Columbia University In The City Of New York	Methods For Treating or Preventing a Vascular Disease
ES2246737B1 (es) *	2005-06-09	2006-12-01	Jose Juan Rodriguez Jerez	"composicion farmaceutica que comprende lisina y usos correspondientes".
CA2635664C (en) *	2005-12-29	2012-09-18	Mitsui Norin Co., Ltd	Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin
US20070265211A1 (en) *	2006-05-12	2007-11-15	Matthias Rath	Novel composition and method effective in inhibiting the atherogenic process
WO2010025335A2 (en) *	2008-08-29	2010-03-04	Dr Pepper/Seven Up, Inc.	Functional consumable compositions for promoting skin health and methods for using the same
EP2179722A1 (en) *	2008-10-24	2010-04-28	Heinrich-Pette-Institut für experimentelle Virologie und Immunologie	Topical formation for preventing sexual transmission of viral infection
ES2534245T3 (es)	2008-11-04	2015-04-20	Vymedic, Llc	Formulaciones de suplemento antiviral
JP4786000B2 (ja) *	2009-10-16	2011-10-05	株式会社カネカ	還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物
TR201816243T4 (tr)	2011-01-31	2018-11-21	Lucolas M D Ltd	Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
KR101829330B1 (ko)	2011-04-13	2018-02-20	(주)아모레퍼시픽	염증성 피부 노화 억제 물질 스크리닝 방법
CN102526170B (zh) *	2011-12-31	2015-04-29	许学志	抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用
BE1023772B9 (fr) *	2013-05-17	2017-08-02	Valore	Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
CN104096058A (zh) *	2014-07-02	2014-10-15	胥玲	一种治疗扩张型心肌病的中药药丸
BE1022579A9 (fr) *	2014-11-10	2016-10-06	Valore	Composition antimétastatique comprenant au moins un composé de type flavanol
IT202200013867A1 (it) *	2022-06-30	2023-12-30	Lo Li Pharma Srl	Composizione per il trattamento dell’ infezione da papilloma virus (hpv)
CN118831080B (zh) *	2024-09-24	2024-11-22	上海交通大学医学院附属仁济医院	5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
TR199900399T2 (xx) *	1996-08-28	1999-06-21	The Procter & Gamble Company	Matris metaloproteaz inhibit�rleri olarak fosfinik asit amidleri.
US5962517A (en) *	1997-01-31	1999-10-05	Murad; Howard	Pharmaceutical compositions and methods for treating acne
US5817695A (en) *	1997-12-24	1998-10-06	Pellico; Michael A.	Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6428818B1 (en) *	1999-03-30	2002-08-06	Purdue Research Foundation	Tea catechin formulations and processes for making same
CA2377414A1 (en)	1999-06-15	2000-12-21	John D. Potter	Nutrient formulations for disease reduction, and related treatment and component screening methods
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
ATE386030T1 (de) *	2002-02-25	2008-03-15	Boehringer Ingelheim Pharma	1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen

2002
- 2002-01-08 US US10/041,427 patent/US6939860B2/en not_active Expired - Fee Related
- 2002-01-31 BR BR0208052-4A patent/BR0208052A/pt not_active IP Right Cessation
- 2002-01-31 MX MXPA04006627A patent/MXPA04006627A/es active IP Right Grant
- 2002-01-31 KR KR10-2004-7010603A patent/KR20050005408A/ko not_active Ceased
- 2002-01-31 TR TR2004/01669T patent/TR200401669T1/xx unknown
- 2002-01-31 CA CA002469162A patent/CA2469162A1/en not_active Abandoned
- 2002-01-31 NZ NZ533353A patent/NZ533353A/en unknown
- 2002-01-31 HR HR20040705A patent/HRP20040705A2/hr not_active Application Discontinuation
- 2002-01-31 SK SK277-2004A patent/SK2772004A3/sk not_active Application Discontinuation
- 2002-01-31 EE EEP200400031A patent/EE200400031A/xx unknown
- 2002-01-31 WO PCT/EP2002/001005 patent/WO2003057211A1/en not_active Ceased
- 2002-01-31 CN CNA028269543A patent/CN1612731A/zh active Pending
- 2002-01-31 PL PL02371205A patent/PL371205A1/xx unknown
- 2002-01-31 AT AT02712877T patent/ATE439833T1/de active
- 2002-01-31 ES ES02712877T patent/ES2332126T3/es not_active Expired - Lifetime
- 2002-01-31 CZ CZ2004853A patent/CZ2004853A3/cs unknown
- 2002-01-31 HU HU0402421A patent/HUP0402421A3/hu unknown
- 2002-01-31 DE DE60233433T patent/DE60233433D1/de not_active Expired - Lifetime
- 2002-01-31 SI SI200220038A patent/SI21871A/sl not_active IP Right Cessation
- 2002-01-31 EP EP02712877A patent/EP1463498B1/en not_active Expired - Lifetime
- 2002-01-31 JP JP2003557569A patent/JP4144800B2/ja not_active Expired - Fee Related
- 2002-01-31 RU RU2004124047/15A patent/RU2284185C2/ru not_active IP Right Cessation
- 2002-01-31 UA UA20040705480A patent/UA78979C2/uk unknown
- 2002-01-31 AU AU2002244690A patent/AU2002244690A1/en not_active Abandoned
- 2002-01-31 IL IL16238402A patent/IL162384A0/xx not_active IP Right Cessation
2003
- 2003-09-05 NO NO20033949A patent/NO20033949L/no not_active Application Discontinuation
2004
- 2004-06-22 ZA ZA200404915A patent/ZA200404915B/en unknown
- 2004-08-05 LT LT2004074A patent/LT5215B/lt unknown
- 2004-09-06 LV LVP-04-88A patent/LV13249B/en unknown
- 2004-09-15 US US10/942,723 patent/US20050032715A1/en not_active Abandoned
2005
- 2005-08-24 US US11/211,389 patent/US20050281794A1/en not_active Abandoned
2008
- 2008-07-16 AU AU2008203157A patent/AU2008203157A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK2772004A3 (en)	2004-12-01
US20030130201A1 (en)	2003-07-10
CA2469162A1 (en)	2003-07-17
UA78979C2 (en)	2007-05-10
EE200400031A (et)	2004-04-15
JP4144800B2 (ja)	2008-09-03
US6939860B2 (en)	2005-09-06
CN1612731A (zh)	2005-05-04
EP1463498A1 (en)	2004-10-06
HUP0402421A3 (en)	2008-02-28
AU2008203157A1 (en)	2008-08-07
TR200401669T1 (tr)	2007-01-22
US20050032715A1 (en)	2005-02-10
LV13249B (en)	2005-07-20
RU2284185C2 (ru)	2006-09-27
AU2002244690A1 (en)	2003-07-24
IL162384A0 (en)	2005-11-20
ES2332126T3 (es)	2010-01-27
NZ533353A (en)	2007-04-27
ATE439833T1 (de)	2009-09-15
BR0208052A (pt)	2005-01-04
RU2004124047A (ru)	2005-04-20
LT5215B (lt)	2005-05-25
CZ2004853A3 (cs)	2004-12-15
DE60233433D1 (de)	2009-10-01
HRP20040705A2 (en)	2004-10-31
EP1463498B1 (en)	2009-08-19
MXPA04006627A (es)	2004-11-10
SI21871A (sl)	2006-04-30
US20050281794A1 (en)	2005-12-22
KR20050005408A (ko)	2005-01-13
NO20033949D0 (no)	2003-09-05
HUP0402421A2 (hu)	2005-07-28
NO20033949L (no)	2003-11-04
ZA200404915B (en)	2006-07-26
JP2005513166A (ja)	2005-05-12
PL371205A1 (en)	2005-06-13
WO2003057211A1 (en)	2003-07-17

Publication	Publication Date	Title
LT2004074A (lt)	2004-12-27	Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti
ZA200305412B (en)	2004-09-02	4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
GB0223038D0 (en)	2002-11-13	Therapeutic compounds
DE60332163D1 (de)	2010-05-27	Zusammensetzung zur hautaufhellung
TR200901979T2 (tr)	2009-05-21	Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
BG108499A (en)	2005-03-31	A novel engineered superantigen for human therapy
MX2007006397A (es)	2007-06-22	Derivados de tetrahidropirano.
NZ331327A (en)	2000-01-28	Serine protease inhibitors having an acylguanidine side chain
WO2003039453A3 (en)	2003-12-04	Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
FR2818906B1 (fr)	2004-04-02	Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
DE60018186D1 (de)	2005-03-24	Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DE50114181D1 (de)	2008-09-11	Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE238791T1 (de)	2003-05-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
EP1251847A4 (en)	2004-11-10	NEW USE OF PRODIGIOSINE TO TREAT DIABETES
ATE242763T1 (de)	2003-06-15	Methoximinophenylessigsäureamide
TW200508196A (en)	2005-03-01	Hydroxamic acids useful in the treatment of hyper-proliferative disorders
ATE247649T1 (de)	2003-09-15	Disubstituierte biphenyloxazoline
WO2004105780A3 (en)	2005-01-20	Compositions comprising gastrin compounds and their use in diabetes
FR2842109B1 (fr)	2007-06-08	Utilisation d'un extrait de chrysanthellum
SE0102185D0 (sv)	2001-06-19	New subject-matter
UA85994C2 (en)	2009-03-25	N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
IL164536A0 (en)	2005-12-18	The use of hydroxypyridone-derivatives in wound healing
UA34199A (uk)	2001-02-15	Спосіб лікування пародонтиту
PT1237850E (pt)	2005-06-30	Glioxilamidas, processo para a sua preparacao e sua utilizacao para o combate de organismos prejudiciais